125 related articles for article (PubMed ID: 30985528)
1. Estimating the Human Papillomavirus Genotype Attribution in Screen-detected High-grade Cervical Lesions.
Lissenberg-Witte BI; Bogaards JA; Quint WGV; Berkhof J
Epidemiology; 2019 Jul; 30(4):590-596. PubMed ID: 30985528
[TBL] [Abstract][Full Text] [Related]
2. Fraction of high-grade cervical intraepithelial lesions attributable to genotypes targeted by a nonavalent HPV vaccine in Galicia, Spain.
Perez S; Iñarrea A; Pérez-Tanoira R; Gil M; López-Díez E; Valenzuela O; Porto M; Alberte-Lista L; Peteiro-Cancelo MA; Treinta A; Carballo R; Reboredo MC; Alvarez-Argüelles ME; Purriños MJ
Virol J; 2017 Nov; 14(1):214. PubMed ID: 29110680
[TBL] [Abstract][Full Text] [Related]
3. Roles of extended human papillomavirus genotyping and multiple infections in early detection of cervical precancer and cancer and HPV vaccination.
Song F; Yan P; Huang X; Wang C; Du H; Qu X; Wu R
BMC Cancer; 2022 Jan; 22(1):42. PubMed ID: 34991494
[TBL] [Abstract][Full Text] [Related]
4. Human papillomavirus genotype distribution and socio-behavioural characteristics in women with cervical pre-cancer and cancer at the start of a human papillomavirus vaccination programme: the CIN3+ plus study.
Egli-Gany D; Spaar Zographos A; Diebold J; Masserey Spicher V; Frey Tirri B; Heusser R; Dillner J; Petignat P; Sahli R; Low N;
BMC Cancer; 2019 Jan; 19(1):111. PubMed ID: 30700274
[TBL] [Abstract][Full Text] [Related]
5. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
[TBL] [Abstract][Full Text] [Related]
6. [Evaluation of CIN2+ /CIN3+ risk of different HPV subtypes infection combined with abnormal cytology status].
Luo HX; Du H; Liu ZH; Zhang LJ; Wang C; Wu RF
Zhonghua Zhong Liu Za Zhi; 2018 Mar; 40(3):232-238. PubMed ID: 29575846
[No Abstract] [Full Text] [Related]
7. High-risk human papillomavirus genotype distribution and attribution to cervical cancer and precancerous lesions in a rural Chinese population.
Zhao XL; Hu SY; Zhang Q; Dong L; Feng RM; Han R; Zhao FH
J Gynecol Oncol; 2017 Jul; 28(4):e30. PubMed ID: 28541628
[TBL] [Abstract][Full Text] [Related]
8. Comparison of measurements of human papillomavirus persistence for postcolposcopic surveillance for cervical precancerous lesions.
Gage JC; Schiffman M; Solomon D; Wheeler CM; Castle PE
Cancer Epidemiol Biomarkers Prev; 2010 Jul; 19(7):1668-74. PubMed ID: 20615884
[TBL] [Abstract][Full Text] [Related]
9. Stratified risk of high-grade cervical disease using onclarity HPV extended genotyping in women, ≥25 years of age, with NILM cytology.
Stoler MH; Wright TC; Parvu V; Yanson K; Cooper CK; Andrews J
Gynecol Oncol; 2019 Apr; 153(1):26-33. PubMed ID: 30638767
[TBL] [Abstract][Full Text] [Related]
10. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
Lehtinen M; Paavonen J; Wheeler CM; Jaisamrarn U; Garland SM; Castellsagué X; Skinner SR; Apter D; Naud P; Salmerón J; Chow SN; Kitchener H; Teixeira JC; Hedrick J; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; De Carvalho NS; Germar MJ; Peters K; Mindel A; De Sutter P; Bosch FX; David MP; Descamps D; Struyf F; Dubin G;
Lancet Oncol; 2012 Jan; 13(1):89-99. PubMed ID: 22075171
[TBL] [Abstract][Full Text] [Related]
11. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
12. Risk of CIN3 or worse with persistence of 13 individual oncogenic HPV types.
Sand FL; Munk C; Frederiksen K; Junge J; Iftner T; Dehlendorff C; Kjaer SK
Int J Cancer; 2019 Apr; 144(8):1975-1982. PubMed ID: 30246864
[TBL] [Abstract][Full Text] [Related]
13. Type-specific HPV prevalence in invasive cervical cancer in the UK prior to national HPV immunisation programme: baseline for monitoring the effects of immunisation.
Mesher D; Cuschieri K; Hibbitts S; Jamison J; Sargent A; Pollock KG; Powell N; Wilson R; McCall F; Fiander A; Soldan K
J Clin Pathol; 2015 Feb; 68(2):135-40. PubMed ID: 25410654
[TBL] [Abstract][Full Text] [Related]
14. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
[TBL] [Abstract][Full Text] [Related]
15. HPV type attribution in high-grade cervical lesions: assessing the potential benefits of vaccines in a population-based evaluation in the United States.
Hariri S; Unger ER; Schafer S; Niccolai LM; Park IU; Bloch KC; Bennett NM; Steinau M; Johnson ML; Markowitz LE;
Cancer Epidemiol Biomarkers Prev; 2015 Feb; 24(2):393-9. PubMed ID: 25416715
[TBL] [Abstract][Full Text] [Related]
16. Human papillomavirus genotypes in cervical intraepithelial neoplasia grade 3.
Castle PE; Schiffman M; Wheeler CM; Wentzensen N; Gravitt PE
Cancer Epidemiol Biomarkers Prev; 2010 Jul; 19(7):1675-81. PubMed ID: 20615885
[TBL] [Abstract][Full Text] [Related]
17. Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants.
Wentzensen N; Schiffman M; Dunn T; Zuna RE; Gold MA; Allen RA; Zhang R; Sherman ME; Wacholder S; Walker J; Wang SS
Int J Cancer; 2009 Nov; 125(9):2151-8. PubMed ID: 19585494
[TBL] [Abstract][Full Text] [Related]
18. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities.
Castle PE; Solomon D; Schiffman M; Wheeler CM
J Natl Cancer Inst; 2005 Jul; 97(14):1066-71. PubMed ID: 16030304
[TBL] [Abstract][Full Text] [Related]
19. Long-term HPV type-specific risks of high-grade cervical intraepithelial lesions: a 14-year follow-up of a randomized primary HPV screening trial.
Smelov V; Elfström KM; Johansson AL; Eklund C; Naucler P; Arnheim-Dahlström L; Dillner J
Int J Cancer; 2015 Mar; 136(5):1171-80. PubMed ID: 25043476
[TBL] [Abstract][Full Text] [Related]
20. Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease.
Joura EA; Ault KA; Bosch FX; Brown D; Cuzick J; Ferris D; Garland SM; Giuliano AR; Hernandez-Avila M; Huh W; Iversen OE; Kjaer SK; Luna J; Miller D; Monsonego J; Munoz N; Myers E; Paavonen J; Pitisuttithum P; Steben M; Wheeler CM; Perez G; Saah A; Luxembourg A; Sings HL; Velicer C
Cancer Epidemiol Biomarkers Prev; 2014 Oct; 23(10):1997-2008. PubMed ID: 25274978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
